Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats.
Unlike severe gastric damage acutely induced by ethanol administration in rat, the ulcerogenic effect of chronic alcohol administration (3.03 g/kg b.w. or 7.28 g/kg b.w.) given in drinking water, producing liver lesions and portal hypertension, is far less investigated. Therefore, focus was on the antiulcer effect of the gastric pentadecapeptide BPC 157, GEPPPGKPADDAGLV, M.W. 1419, known to have a beneficial effect in variety of gastrointestinal lesions models (10 microg or 10 ng/kg b.w. i.p. or i.g.), ranitidine (10 mg/kg b.w. i.g.) and propranol (10 mg/kg b.w. i.g.) or saline (5 ml/kg b.w. i.p./i.g.; control). They were given once daily (1) throughout 10 days preceding alcohol consumption, (2) since beginning of alcohol drinking till the end of the study, (3) throughout the last month of alcohol consumption, 2 months after alcohol drinking had been initiated. Gastric lesions were assessed, at the end of 3 months drinking [(1), (2)] or with respect to therapeutic effect of medication before medication or at the end of therapy. Pentadecapeptide BPC 157, ranitidine and propranolol may prevent gastric lesion development if given prophylactically, before alcohol drinking. Likewise, they attenuate the lesion appearance given once daily throughout the drinking period. Importantly, when given therapeutically, they may antagonize otherwise pertinent lesion presence in stomach mucosa of the drinking rats. Thus, these results demonstrate that pentadecapeptide BPC 157, ranitidine and propranol may prevent, attenuate or reverse the gastric lesions appearance in chronically alcohol drinking rats, and may be used for further therapy, while the other studies showed that their effect (except to ranitidine) is parallel with their beneficial effect on liver lesion and portal hypertension.
Prkacin
I
I
Department of Pharmacology, Medical Faculty University of Zagreb, Salata 11, PO Box 916, Zagreb, Croatia.
Aralica
G
G
Perovic
D
D
Separovic
J
J
Gjurasin
M
M
Lovric-Bencic
M
M
Stancic-Rokotov
D
D
Ziger
T
T
Anic
T
T
Sikiric
P
P
Seiwerth
S
S
Staresinic
M
M
Mise
S
S
Rotkvic
I
I
Jagic
V
V
Rucman
R
R
Petek
M
M
Turkovic
B
B
Marovic
A
A
Sjekavica
I
I
Sebecic
B
B
Boban-Blagaic
A
A
Ivasovic
Z
Z
D000428:Alcohol Drinking; D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D019610:Cytoprotection; D008297:Male; D010446:Peptide Fragments / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology*; D011506:Proteins / Q000494:pharmacology*; D011899:Ranitidine / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013272:Stomach Diseases / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors
D000897:Anti-Ulcer Agents; D010446:Peptide Fragments; D011506:Proteins; D011899:Ranitidine; C083833:BPC 157; D011433:Propranolol